Nurix Therapeutics Inc (NRIX) returns
Nurix Therapeutics returns over 5 years
$1,000 invested in Nurix Therapeutics five years ago was worth $801.20 at the close on October 30, 2026, with dividends reinvested: an average return of -4.3% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | +13.0% | — | $1,130 | -0.9% |
| 3 months | +13.7% | — | $1,137 | +2.1% |
| Year to date | +41.3% | — | $1,413 | +11.7% |
| 1 year | +109.7% | — | $2,097 | +12.4% |
| 3 years | +409.5% | +72.1% | $5,095 | +88.5% |
| 5 years | -19.9% | -4.3% | $801.20 | +76.0% |
Nurix Therapeutics return by calendar year
| Year | NRIX | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | +41.3% | +11.7% | +29.6% |
| 2025 | +0.7% | +17.7% | -17.0% |
| 2024 | +82.6% | +24.9% | +57.7% |
| 2023 | -6.0% | +26.2% | -32.2% |
| 2022 | -62.1% | -18.2% | -43.9% |
| 2021 | -12.0% | +28.7% | -40.7% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: NRIX financials · NRIX valuation
No forecast, no recommendation. This page describes Nurix Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.